Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02SRB
|
||||
Former ID |
DIB011708
|
||||
Drug Name |
BPL-001
|
||||
Synonyms |
HMG CoA reductase inhibitors (cardiovascular disease), Bradford Pharma; HMG CoA reductase inhibitors (cardiovascular disease), Redx Pharma; BPL-001 series (cardiovascular disease), Bradford Pharma; BPL-001 series (cardiovascular disease), Redx Pharma
|
||||
Indication | Cardiovascular disorder [ICD10:I00-I99] | Investigative | [1] | ||
Company |
Bradford Pharma Ltd
|
||||
Target and Pathway | |||||
Target(s) | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Target Info | Inhibitor | [1] | |
BioCyc Pathway | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | ||||
Superpathway of cholesterol biosynthesis | |||||
Mevalonate pathway | |||||
KEGG Pathway | Terpenoid backbone biosynthesis | ||||
Metabolic pathways | |||||
Biosynthesis of antibiotics | |||||
AMPK signaling pathway | |||||
Bile secretion | |||||
NetPath Pathway | IL5 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
TSH Signaling Pathway | |||||
PANTHER Pathway | Cholesterol biosynthesis | ||||
PathWhiz Pathway | Steroid Biosynthesis | ||||
WikiPathways | Statin Pathway | ||||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
Activation of Gene Expression by SREBP (SREBF) | |||||
SREBF and miR33 in cholesterol and lipid homeostasis | |||||
Integrated Breast Cancer Pathway | |||||
SREBP signalling | |||||
Cholesterol Biosynthesis | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.